Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05959629 · ClinicalTrials.gov registry record · NA
Erbium, Chromium: Yttrium, Scandium, Gallium, Garnet (Er,Cr:YSGG) Laser in Root Canal Disinfection
A NA study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT05959629: Clinical Trial NA study, sponsored by University of Pennsylvania.
NCT05959629 is a NA study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05959629, a NA study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a protocol for biofilms disinfection with a FDA cleared, clinically approved and commercially available Er,Cr:YSGG laser treatments. This protocol will be testing local single topical application of Lasers within the canal system in patients going through routine endodontic treatment, evaluate its potential as anti-biofilm treatment and compare it to other currently used antibacterial protocols.
Primary Outcome
By measuring change in bacteria colony forming units (CFU) before and after treatment for the experimental group (laser) and the standard of care (NaOCl) group, then comparing the two groups.
Interventions
- DEVICE Waterlase Express™, BIOLASE®
- OTHER Sodium Hypochlorite
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2024-05-02 |
| Phase | NA |
Why NCT05959629 stopped before completion
NCT05959629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Waterlase Express™, BIOLASE® is the first listed.
NCT05959629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05959629 about?
NCT05959629 is a clinical study titled "Erbium, Chromium: Yttrium, Scandium, Gallium, Garnet (Er,Cr:YSGG) Laser in Root Canal Disinfection". The purpose of this study is to develop a protocol for biofilms disinfection with a FDA cleared, clinically approved and commercially available Er,Cr:YSGG laser treatments. This protocol will be testing local single topical application of Lasers within the canal system in patients going through rout...
What is the current status of trial NCT05959629?
This trial is currently terminated. It is a NA study. The enrollment target is 56 participants. The study started on 2023-10-11. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT05959629?
The interventions under investigation include: Waterlase Express™, BIOLASE® (DEVICE), Sodium Hypochlorite (OTHER).
Who is sponsoring clinical trial NCT05959629?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05959629's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI